BRAF and Langerhans cell histiocytosis: Notably, LCH patients with SUVmax > 7.5 exhibited significantly reduced remission rates (p = 0.032), corroborating Park et al.’s findings that SUVmax reflects tumor proliferative activity and potential BRAF mutation associations (19).